Riskpilot← Back to searchSign inGet full accessMedTravest II ApS
APSActiveCVR 42368032Vestergade 48Activities of holding companies · NACE 6421Est. 2021— employees
Revenue 2024
DKK -19K
+1% vs 2023
EBITDA margin
100.0%
-1% vs 2023
Equity ratio
99.0%
Financial strength
Net profit 2024
DKK -24K
-26% vs 2023
| Revenue | DKK -19K | +1% |
| EBITDA | DKK -19K | -1% |
| Net profit | DKK -24K | -26% |
| Total assets | DKK 7,7M | +0% |
| Equity | DKK 7,6M | +0% |
| Employees | — | — |
Legal name
MedTravest II ApS
CVR number
42368032
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
23. april 2021
Share capital
DKK 7.873.966
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at finansiere og investere i MedTrace Pharma A/S og associerede virksomheder.
Address
Vestergade 48
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | — | -19 | -19 |
| Staff expenses | -0 | -0 | -0 | -0 |
| EBITDA | -39 | -35 | -19 | -19 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -39 | -35 | -19 | -19 |
| Net financials | -3 | -2 | 0 | -5 |
| Profit before tax | -42 | -38 | -19 | -24 |
| Tax | -0 | -0 | -0 | -0 |
| Net profit | -42 | -38 | -19 | -24 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 3.117 | 7.700 | 7.719 | 7.725 |
| Equity | 3.064 | 7.686 | 7.667 | 7.644 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 53 | 14 | 52 | 81 |
| Total debt | 53 | 14 | 52 | 81 |
EBITDA margin
-1900000.0%
This company
15.8%
Market median
-12025416% vs market
20212024
Equity ratio
99.0%
This company
38.2%
Market median
+159% vs market
20212024
Return on equity
-0.3%
This company
18.4%
Market median
-102% vs market
20212024
Net profit margin
-2354600.0%
This company
8.1%
Market median
-29069236% vs market
20212024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-04-23 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PJ Management | Management | 2023 | — | — |
BS Management | Management | 2021 | — | — |
JS Management | Management | 2025 | — | — |
PA Management | Management | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
MedTravest A/S | Company | 25.0% | 25.0% | 2021 |
STRATHE INVEST ApS | Company | 20.0% | 20.0% | 2021 |
JUUL KRISTENSEN HOLDING ApS | Company | 20.0% | 20.0% | 2021 |
MLU Holding af 10/1-2017 ApS | Company | 10.0% | 10.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
JUUL KRISTENSEN HOLDING ApS
MedTravest II ApS Board members of MedTravest II ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Juul Kristensen | Management | 0 companies |
| Bernt Skov Jensen | Management | 0 companies |
| Jens Strathe | Management | 0 companies |
| Peter Andreas Stakemann | Management | 0 companies |
| Mark Lund Andersen | Chairman | 0 companies |
| Tore Jesper Andersen | Board of Directors | 0 companies |